mTOR signaling in aging: from causality to geroprotective interventions and hallmark-level outcomes
What this study shows
Frames mTOR as a dynamic, context-dependent signaling hub integrating nutrient sensing, proteostasis, autophagy and stress adaptation across the hallmarks of aging; surveys geroprotective interventions (autophagy activation, dietary restriction, exercise, senotherapeutics) that partly converge on mTOR signaling. Causal evidence for mTOR in lifespan regulation is strong in model organisms; human data remain associative but biologically consistent.
Abstract
ShowHide
The mechanistic target of rapamycin (mTOR) pathway is an important integrator of processes involved in aging and longevity, coordinating nutrient sensing, metabolic adaptation, and cellular stress responses. This review presents a three-section framework in which mTOR functions as a dynamic signaling hub coordinating multiple biological processes underlying the aging process.
Read the full abstract on PubMed →At a glance
ShowHide
| Evidence type | R Review — secondary literature, not a new result Marked R because it is a review or synthesis of existing evidence rather than a new primary result; that is a different form of writing, not a weaker one. |
| Study type | Narrative Review |
| Model system | Narrative review synthesis (model organisms + human associative data) |
| Journal | Aging |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.18632/aging.206423 · PMID 42765942 |
Where this study fits
How this study connects to the pathway map, open questions, people and other studies in the Atlas.
People in the Atlas
-
Physician-scientist and founder of a Swiss longevity/skincare company; author of a 2026 review situating mTOR as an integrative signaling hub across the hallmarks of aging
Related studies
- A Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster
JAC2026 · 2026 · Shares: Longevity, mTOR
- R Rapamycin across biology and medicine: From molecular mechanisms to clinical and translational frontiers
NOL2026 · 2026 · Shares: Longevity, mTOR
- S
- R Nutrient-sensing pathways in adult stem cells: Orchestrating homeostasis, aging, and disease
XIA2026 · 2026 · Shares: Longevity, mTOR
- RT
More related studies
- R What is the clinical evidence to support off-label rapamycin therapy in healthy adults?
HAN2025 · 2025 · Shares: Longevity, mTOR
- H Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
MOE2025 · 2025 · Shares: Longevity, mTOR
- S Targeting ageing with rapamycin and its derivatives in humans: a systematic review
LEE2024 · 2024 · Shares: Longevity, mTOR
- A
- A DNA methylation age analysis of rapamycin in common marmosets.
HOR2021 · 2021 · Shares: Longevity, mTOR
- R mTOR at the nexus of nutrition, growth, ageing and disease
LIU2020 · 2020 · Shares: Longevity, mTOR
- A A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
URF2017 · 2017 · Shares: Longevity, mTOR
- A Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
BIT2016 · 2016 · Shares: Longevity, mTOR
Topics
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | none (narrative review) |
| Target | mTORC1 / mTORC2 signalling across hallmarks of ageing |
| Model | Model organisms and human associative data (review) |
| Effect | Argues mTOR is a context-dependent hub in ageing, with causal evidence in model organisms and associative evidence in humans. |
Thank you. Your answer was counted anonymously.